General Information of Drug (ID: DMLK428)

Drug Name
D-Phe-Arg-2-Nal-NHCH3 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMLK428

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [2]
Afamelanotide DMVWHTG Erythropoietic porphyrias 5C58.12 Approved [3]
Dersimelagon DMMO0SU Erythropoietic protoporphyria 5C58.12 Phase 3 [4]
PL8177 DML5V22 Ulcerative colitis DD71 Phase 2 [5]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [6]
MT-II DMKT1DA Female sexual arousal dysfunction HA01.1 Investigative [7]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO Discovery agent N.A. Investigative [8]
Ac-YRMEHdFRWG-NH2 DMN2UKC Discovery agent N.A. Investigative [9]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ Discovery agent N.A. Investigative [8]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylnaltrexone bromide DMZTGN2 Opioid-induced constipation DB32.1 Approved [10]
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [2]
Setmelanotide DMPVRN9 Obesity 5B81 Approved [11]
Amylin DMWDEN0 N. A. N. A. Phase 4 [12]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [10]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [13]
PF-446687 DML38VU Female sexual arousal dysfunction HA01.1 Phase 2 [14]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [6]
PF-07258669 DM3CJ5N Malnutrition 5B50-5B71 Phase 1 [15]
PT-14 DMYM9JL Erectile dysfunction HA01.1 Discontinued in Phase 2 [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocortin receptor 1 (MC1R) TT0MV2T MSHR_HUMAN Inhibitor [1]
Melanocortin receptor 4 (MC4R) TTD0CIQ MC4R_HUMAN Inhibitor [1]

References

1 Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic ap... J Med Chem. 2006 Jul 27;49(15):4745-61.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022 Sep 1;24(1):210.
5 Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration. Drugs R D. 2021 Dec;21(4):431-443.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9.
8 Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
9 Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
10 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
12 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
13 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
14 Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
15 Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
16 The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.